Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening-Reference-Cited by-同舟云学术

Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening

Published:2022-10-27 Issue:21 Volume:65 Page:14391-14408
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Tian Xinrong¹^ORCID,Suarez Dominic¹,Thomson Douglas²,Li William¹,King Elizabeth A.¹^ORCID,LaFrance Louis¹,Boehm Jeffrey¹,Barton Linda¹,Di Marco Christina¹,Martyr Cuthbert¹,Thalji Reema¹,Medina Jesus¹,Knight Steven¹,Heerding Dirk¹,Gao Enoch¹,Nartey Eldridge¹,Cecconie Ted¹,Nixon Christopher¹,Zhang Guofeng¹,Berrodin Thomas J.¹,Phelps Christopher³,Patel Amish³,Bai Xiaopeng³,Lind Ken³,Prabhu Ninad³,Messer Jeffrey³^ORCID,Zhu Zhengrong³^ORCID,Shewchuk Lisa¹,Reid Rob¹,Graves Alan P.¹^ORCID,McHugh Charles¹,Mangatt Biju¹

Affiliation:

1. Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States

2. Cellzome GmbH, A GlaxoSmithKline Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany

3. New Chemical Entity Molecular Discovery, GlaxoSmithKline, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00670

Reference33 articles.

1. Acetylation and deacetylation in cancer stem-like cells